Elicio Therapeutics Q1 2024 Adj EPS $(1.15) Misses $(1.09) Estimate
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics (NASDAQ:ELTX) reported a Q1 2024 adjusted EPS of $(1.15), missing the analyst consensus estimate of $(1.09) by 5.5%.
May 15, 2024 | 8:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Elicio Therapeutics reported a Q1 2024 adjusted EPS of $(1.15), missing the analyst consensus estimate of $(1.09) by 5.5%. This earnings miss could negatively impact the stock price in the short term.
The earnings miss indicates that the company's financial performance was below expectations, which typically leads to a negative reaction from investors and a potential decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100